Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat^® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed July 15, 2013
   Google Scholar
• HananiaNADonohueJFPharmacologic interventions in chronic obstructive pulmonary disease. BronchodilatorsProc Am Thorac Soc20074752653417878465
   PubMedGoogle Scholar
• AndersonGPFormoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2- adrenoceptor agonist bronchodilatorLife Sci19935226214521608099696
   PubMed Web of Science ®Google Scholar
• BallDIBrittainRTColemanRASalmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivoBr J Pharmacol199110436656711686740
   PubMed Web of Science ®Google Scholar
• MaesenFPVSmeetsJJSledsensTJHWaldFDMCornelissenPJGDutch study groupTiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)Eur Respir J199589150615138575576
   PubMed Web of Science ®Google Scholar
• LittnerMRIlowiteJSTashkinDPLong-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20001614 Pt 11136114210764302
   PubMed Web of Science ®Google Scholar
• BauwensONinaneVVan de MaeleB24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolCurr Med Res Opin200925246347019192991
   PubMed Web of Science ®Google Scholar
• RauJLDeterminants of patient adherence to an aerosol regimenRespir Care200550101346135616185370
   PubMedGoogle Scholar
• RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic reviewChest201214251104111022383666
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther2011337360060921357659
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• O’ByrnePMvan der LindeJCockcroftDWProlonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthmaJ Allergy Clin Immunol200912461217122120004781
   PubMed Web of Science ®Google Scholar
• van NoordJAKorduckiLHamiltonAKokerPFour weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patientsAm J Respir Crit Care Med2009179A6183 (abstract)
   Web of Science ®Google Scholar
• JoosGAumannJLCoeckCKorduckiLHamiltonALvan NoordJComparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPDAm J Respir Crit Care Med2012185A2930 (abstract)
   Google Scholar
• O’ByrnePMD’UrzoTGahlemannMHartLWangFBeckEDose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthmaAm J Respir Crit Care Med2012185A3963 (abstract)
   Google Scholar
• European Medicines AgencyGuideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdfAccessed August 7, 2013
   Google Scholar
• MahlerDAMechanisms and measurement of dyspnea in chronic obstructive pulmonary diseaseProc Am Thorac Soc20063323423816636091
   PubMedGoogle Scholar
• MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMThe St. George’s Respiratory QuestionnaireResp Med199185Suppl B2531
   PubMed Web of Science ®Google Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
   PubMed Web of Science ®Google Scholar
• SiddiquiOHungHMO’NeillRMMRM vs. LOCF: a comprehensive comparison based on simulation study and 36 NDA datasetsJ Biopharm Stat200919222724619212876
   PubMed Web of Science ®Google Scholar
• LittleRJWangYPattern-mixture models for multivariate incomplete data with covariatesBiometrics1996521981118934587
   PubMed Web of Science ®Google Scholar
• Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education, National Research CouncilThe Prevention and Treatment of Missing Data in Clinical TrialsWashington DCNational Academies Press2010
   Google Scholar
• HoganJWRoyJKorkontzelouCHandling drop-out in longitudinal studiesStat Med20042391455149715116353
   PubMed Web of Science ®Google Scholar
• IchinoseMTakizawaAIzumotoTFukuchiYEfficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting β2-agonist, in Japanese patients with COPDAm J Respir Crit Care Med2012185A2931 (abstract)
   Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studiesEur Respir J201342Suppl 57146sP764 (abstract)
   Google Scholar
• FergusonGFeldmanGHofbauerPLung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studiesEur Respir J201342Suppl 575s187 (abstract)
   Google Scholar
• LangePAumannJ-LDeromEThe 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studiesEur Respir J201342Suppl 57982s4635 (abstract)
   Google Scholar
• McGarveyLKochASachsP48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysisEur Respir J201342Suppl 57749sP3633 (abstract)
   Google Scholar
• JoosGAumannJLCoeckCKorduckiLHamiltonALvan NoordJAComparison of 24-hour FEV₁ profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β₂agonist, in patients with COPDPoster A2930 presented at the 103rd Annual International Conference of the American Thoracic SocietySan Francisco, CA, USAMay 18–23, 2012
   Google Scholar
• FeldmanGBernsteinJHamiltonANivensCWangFLaForceCThe 24-hour FEV₁ time profile of olodaterol once daily (QD) via Respimat^® and formoterol twice daily (BID) via Aerolizer^® in patients with COPD: results from two 6-week studiesAbstract 749A presented at CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar
• KochAPaggiaroPHamiltonASymptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studiesEur Respir J201342Suppl 57145sP763 (abstract)
   Google Scholar
• MaltaisFKirstenAHamiltonADe SousaDWangFDecramerMEvaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studiesAbstract 748A presented at CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• BouyssouTSchnappACasarosaPPieperMPAddition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical modelsAm J Respir Crit Care Med2010181A4445 (abstract)
   Google Scholar
• BouyssouTCasarosaPPieperMSchnappAGantnerFSynergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigsEur Respir J201138Suppl 55613s3451 (abstract)
   Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patientsEur Respir J201036Suppl 541014s5557 (abstract)
   Google Scholar
• AalbersRMaleki-YazdiMRHamiltonADose-finding study for tiotropium and olodaterol when administered in combination via the Respimat^® inhaler in patients with COPDAbstract 2882 presented at the European Respiratory Society Annual CongressVienna, AustriaSeptember 1–5, 2012
   Google Scholar